---
schema_version: "secwatch.filing_event.v1"
accession: "0001613103-25-000019"
form_type: "8-K"
ticker: "MDT"
cik: "0001613103"
company_name: "Medtronic plc"
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T16:31:29.430735+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Medtronic Q3 FY2025 revenue $8.3B, EPS $1.39 non-GAAP beat; organic growth 4.1%

## Summary
- Revenue $8.292B (+2.5% reported, +4.1% organic); GAAP EPS $1.01 (+2%), non-GAAP EPS $1.39 (+7%, above guidance).
- Cardiovascular up 5% organic led by PFA (low-20s growth) and Micra (mid-20s growth); Diabetes up 10.4% organic.
- Neuroscience up 5.2% organic (Neuromodulation low-double digit); Medical Surgical down 0.4% organic.
- FY25 guidance reaffirmed: organic rev growth 4.75%-5%, non-GAAP EPS $5.44-$5.50.
- CMS opened NCA for Renal Denervation; FDA approved additional PFA manufacturing site in Galway.

## SEC filing metadata
- accession: 0001613103-25-000019
- form_type: 8-K
- ticker: MDT
- cik: 0001613103
- company_name: Medtronic plc
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613103/000161310325000019/0001613103-25-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613103/000161310325000019/mdt-20250218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001613103-25-000019
- JSON: https://secwatch.observer/filing/0001613103-25-000019.json
- Plain text: https://secwatch.observer/filing/0001613103-25-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.